This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
If approved, venetoclax will compete in the market with other new therapies for CLL, including Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib), which
Specifically, England's drug pricing watchdog has opened a consultation on its preliminary draft guidance for the drug Zydelig (idelalisib) for patients with chronic lymphocytic leukaemia (CLL).
nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the
Revlimid (lenalidomide). Myeloma. Eisai. Halaven (eribulin). Breast cancer. Gilead Sciences. Zydelig (idelalisib).
Zydelig (idelalisib) has been approved by the European Commission for use in the treatment of patients with chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL).
Just last week the European Medicines Agency (EMA) issued recommendations to both Janssen's Imbruvica (ibrutinib) and Gilead's Zydelig (idelalisib) in CLL indications.
More from news
Approximately 2 fully matching, plus 15 partially matching documents found.